Abstract

Introduction

The causative agent of an infectious disease whose incidence is increasing following its appearance in a new host population or whose incidence is increasing in an existing population as a result of long-term changes in its underlying epidemiology or the development of antimicrobial resistance has been defined as an emerging antibiotic-resistant pathogen.¹ Carbapenem-resistant Enterobacteriaceae (CRE) infections result in longer hospital admissions, higher healthcare costs, and increased mortality than carbapenem-susceptible bacterial infections.²

The Enterobacteriaceae family includes many bacteria that are commonly isolated from clinical cultures, including Escherichia coli, Klebsiella spp., and Enterobacter spp. Because Enterobacteriaceae are a common cause of both community and healthcare-related diseases, they are particularly important in the context of antibiotic resistance.³ The Enterobacteriaceae family has developed through time and has an innate ability to proliferate by developing resistance to antimicrobial chemicals provided, rendering existing antibacterial ineffective, and emerging as resistant to carbapenem, a last-line antibiotic.^4,5

In the human and animal colons, Enterobacteriaceae is mostly found as part of the normal flora. According to the World Health Organization’s antimicrobial resistance report, Enterobacteriaceae resistant to carbapenem are classified as a critical group and developing drug-resistant infections.^6,7 According Centers for Disease Control (CDC) description of the antimicrobial-resistant pathogens, CRE such as Klebsiella species, Escherichia coli (E.coli) and Enterobacter species are the most crucial emerging resistance threats in the global.⁸

Bacterial infections caused by CRE, which are resistant to all classes of current antimicrobial drugs, have become a serious endpoint in the fight against bacterial infections in public health.^9–11 Furthermore, the rise of carbapenem resistance and rapid dissemination of the Enterobacteriaceae family are referred to as “superbugs bacteria”.^12,13

Because of the emergence of the CRE family, therapeutic approaches are no longer effective, and infections are more difficult to cure with the commonly used medications. As a result, infections would spread, longer hospital admissions would increase economic and social expenses, and death would rise.¹⁴ Carbapenem-resistant bacteria pneumonia, urinary tract infections, septicemia, endocarditis, meningitis, and severe intra-abdominal infections are only a few of the illnesses caused by Enterobacteriaceae.¹⁵ Due to the synthesis of extended spectrum beta-lactamase (ESBL), Enterobacteriaceae have developed resistance to third-generation cephalosporins, making therapy very challenging.¹⁶ The introduction and spread of bacteria resistant to carbapenems, on the other hand, puts their effectiveness in threat.^17,18 To combat this threat, the medical community turned to broader spectrum agents and carbapenems, which in turn contributed to resistance due to selection and increased the emergence of increasingly resistant organisms.¹⁹

Carbapenem resistance in Enterobacteriaceae is mostly expressed by the synthesis of carbapenemase enzymes, which are encoded by numerous genotypes and can be transferred among Enterobacteriaceae via transferable genetic elements. Commonly pronounced enzymes include Class A Klebsiella pneumoniae carbapenemase, Class B metallo-β- lactamases, and Class D OXA β-lactamases.²⁰ Resistance can also be developed through efflux pumps, permeability changes caused by the loss of outer membrane porin, or target mutations.²¹ Resistance is enhancement to be a continuous evolutionary process in the Enterobacteriaceae family. Mutation is a type of genetic change that occurs frequently in nature. Mutations in genetic structures can affect a cell’s ability to grow and survive in the presence of environmental stresses like antimicrobials.²²

However, novel medications for treating CRE infection have just been accessible, and several more are in the works. While traditional drugs such as fosfomycin, tigecycline, minocycline, polymyxin and other therapeutic alternatives are still being used as therapy for CRE infections, recently emerged drugs including meropenem–vaborbactam, imipenem–relebactam, plazomicin, cefiderocol, eravacycline, and aztreonam–avibactam are more potent against CRE infections with fewer side effects and toxicities. Moreover, copper oxide nanoparticles, phage therapy and varieties of candidate vaccines have also influenced the development of Shigellosis infection.²³

This review aims to provide an update on the rising carbapenem-resistant Enterobacteriaceae, its epidemiology as well as novel treatment options against these increasingly resistant bacteria.²⁴

Literature Review

Epidemiology

Multidrug-resistant Enterobacteriaceae (MDR-E) is thought to have initially arisen in the 1980s, shortly after the widespread use of cephalosporins and other broad-spectrum ß-lactam antibiotics. SHV and TEM were among the first ESBLs found, followed by CTX-M, which have now expanded to become the most common plasmid-mediated ß-lactamases worldwide. Different carbapenemase-producing Enterobacteriaceae are becoming more prevalent in different parts of the world, according to epidemiological data. Carbapenem-resistant strains were initially discovered in the 1980s and rapidly spread over the world.⁴³

New Delhi metallo-ß-lactamase-1 is the most common carbapenemase generating resistance in India, Pakistan, and Sri Lanka. KPC-producing Enterobacteriaceae, on the other hand, are found in the United States, Colombia, Argentina, Greece, and Italy, and OXA-48-like enzyme-producers are found in Turkey, Malta, the Middle East, and North Africa.⁴⁴ Another study from 2011 to 2014 in the United States found 10% carbapenem resistance in Klebsiella pneumoniae and 16–36% third-generation cephalosporin (3rd GC) resistance in Escherichia coli.⁴⁵ Another study using clinical isolates in Europe found that K. pneumonia is resistant to third GC in 31% of the cases, while E. coli is resistant to carbapenem in 8% of the cases and third GC in 12% of the cases.⁴⁶

Before 2001, the Greek System for Antibiotic Resistant Research showed a carbapenem resistance rate of 1%; by 2008, this had risen to 30% in hospital wards and 60% in intensive care units. According to data from the European Centre for Disease Prevention and Control’s EARS-Net, 678 (62.3%) of 1088 Greek K. pneumoniae isolates were carbapenem-resistant in 2014.⁴⁷ In the state of Israel, in 2008 and 2013, two cross-sectional nationwide surveys of CP Enterobacteriaceae (CPE) in Israeli post-acute-care hospitals revealed a considerable drop in the overall incidence of carbapenem resistance among Enterobacteriaceae isolates (184 of 1147 isolates (16%)). KPC-carrying K. pneumoniae, on the other hand, remained the most common CPE, with a growing proportion of ST258 K. pneumoniae strains (120 of 184 (65%) in 2008 versus 91 of 113 (80%) in 2013).⁴⁸

The Meropenem Annual Drug Susceptibility Data Gathering surveillance system mentioned 57 isolates in 2006, with 9.5% of the gathering characterized as clonal blaKPC-producing Klebsiella strains, representing a twofold increase from the previous year; most isolates were from states in the Mid-Atlantic US Census division, and hospital prevalence rates ranged from 2.4% in Ohio to 9.5% in Pennsylvania; most isolates were from states in the Mid-Atlantic.^49,50 The spread of KPC-producing bacteria across the United States is clear; according to the same surveillance program, 28 of 195 Enterobacteriaceae isolates (14.4%) tested from 26 US medical centers had blaKPC-2 or blaKPC-3 by 2010, with 9 of the 28 discovered in Texas.⁵¹ In Egypt and other African countries, carbapenem resistance is common and spreading, with more than half of hospitals (64%) having at least one CRE isolate and half (47.9%) of Enterobacteriaceae isolates being CRE, which is greater than estimates from other Arab, African, and Asian countries.⁵²

In general, all countries are at risk of being victims to the emergence of carbapenem-resistant Enterobacteriaceae infection with growing prevalence has been reported worldwide.⁷⁴

Prevention and Control

Infections can be controlled by using a multidimensional, coordinated strategy and following infection prevention principles. Specifically, by reducing CRE transmission from person to person.⁷⁵ Essentially, avoiding unnecessary or misuse of invasive equipment such as indwelling urinary catheters or IV lines, medical staff hand washing, greater barrier measures, and isolation of patients colonized or infected with carbapenemase producers. Infection management strategies are primarily focused on stopping the spread of such organisms from patient to patient. Apart from that, the main issues are healthcare professionals’ hand hygiene, the use and cleaning of medical equipment, and environmental colonization; early implementation of active surveillance through rectal screening for CRE carriage on hospital admission, environmental cleaning, staff education, case notification/flagging, and contact tracing are all necessary to prevent spreading and outbreaks of carbapenemase-producing bacteria spread and outbreaks.⁶

Generally, educating health care workers, using infection control and antimicrobial stewardship, and active surveillance for halting the chain of transmission should all be part of a proactive approach to tackling antimicrobial resistance at a regional, national, and international level.⁵³

Principal Treatment Options

For infections caused by ESBL and AmpC producers, carbapenems are the preferred treatment options. CRE, on the other hand, are resistant to practically all beta-lactams, with a few exceptions, and older antibiotic groups that have acceptable action. As a result, CRE therapy options are more limited, with older treatments such as aminoglycosides, polymyxins, a glycylcycline, and Fosfomycin being particularly effective.⁷⁶ Although polymyxins are effective against CRE, they have nephrotoxicity and neurotoxicity as adverse effects, as well as poor effectiveness against Proteus, Providencia, Morganella, and Serratia infections.⁷⁷

Because tigecycline has a higher binding affinity with ribosomal sites than tetracycline, it has been shown to be an effective therapeutic against Enterobacteriaceae that are resistant to tetracycline.⁷⁸ Tigecycline is effective against practically all ESBLs and multidrug-resistant (MDR) E. coli isolates, as well as the vast majority of ESBL and MDR Klebsiella isolates. However, their activity against Proteus, Providencia, and Morganella is limited.⁷⁸ Nevertheless, due to its low penetration and quick tissue diffusion after being intravenously administered, tigecycline has unsatisfactory clinical effects in both urinary tract and main blood infections, making it ineffective.⁷⁹

Fosfomycin is an antibacterial drug that works against CRE by inhibiting the enzyme UDP-N-acetylglucosamine enol pyruvyl transferase (MurA), which catalyzes one of the first steps in bacterial cell wall production. However, it has limited use to treatment for lower urinary tract infections. In vitro and retrospective investigations suggest that, at least for KPC infections, combined therapy with a carbapenem (eg, polymyxin–carbapenem or aminoglycoside–carbapenem) is more effective.⁸⁰

In the case of OXA-48 and NDM infections, a recent retrospective observational analysis concluded that combined therapy with colistin is the best treatment option. Because existing antimicrobial medicines have limitations, new and effective antimicrobial drugs are required for CRE infections.⁸¹ Except for the monobactam aztreonam, aztreonam/avibactam MBLs can hydrolyze any beta-lactams (ATM). However, due to the fact that MBL-producing Enterobacteriaceae frequently produce serine-lactamases, which can hydrolyze aztreonam, aztreonam is only effective against about 30% of these isolates. As a result, combining ATM with a -lactam/-lactamase inhibitor like ceftazidime–avibactam (CAZ-AVI) has proven to be an appealing combination with synergistic in vitro efficacy, especially against infections that produce both metallo- and serine-lactamases.⁸² Cefiderocol is a new siderophore cephalosporin that enters the bacterial cell via iron transporters, avoiding resistance induced by porin channel mutations and efflux pump overproduction. Cefiderocol also has other chemical structural characteristics that offer greater efficacy against Gram-negative bacteria that are difficult to treat, as well as stability against hydrolysis by different beta-lactamases in vitro, including MBL.⁸³

Scientists are concentrating on developing new antibacterial medications to address these pressing challenges b-lactamase inhibitor (NB-BLI) which is avibactam combination with ceftazidime. Ceftazidime–avibactam (CAZ-AVI) is an intravenous cephalosporin/beta-lactamase, which is currently available on the market, and it is also being tested in conjunction with aztreonam and ceftaroline.⁸⁴

Contrasting to other β-lactamase inhibitors, avibactam is not a β-lactam. Rather, its diazabicyclooctane structure mimics a β-lactam and is capable of hindering β-lactamases belonging to Strider classes A and C, and some class D enzymes.⁸⁵ Despite not possessing antibacterial activity on its own, avibactam broadens the spectrum of ceftazidime’s activity. In isolates of E. coli, Enterobacter spp., and Klebsiella spp. that are carbapenem-resistant or express extended-spectrum B-lactamases, AmpC, OXA-48, KPC, and other resistance mechanisms, this combination enhances sensitivity to ceftazidime by 16- to 1024-fold.^85,86

Despite the fact that combination therapy is now the gold standard for treating CRE infections, resistance, treatment failure, and toxicity have prompted the development of new therapeutic approaches.⁸⁷ Unfortunately, several drugs with anti-CRE activity are in late-stage research. Among these under pipelines agents are plazomicin, relebactam + imipenem, eravacycline, zidebactam and meropenem + novel β-lactamase inhibitor. Each drug is detailed in Table 2.

Overall, therapy must be tailored to the patient’s susceptibility profile, type and degree of infection, and personal characteristics. Beyond those unique treatment options, nano-strategies (using nanoparticles) to combat multidrug-resistant bacteria, such as carbapenem-resistant Enterobacteriaceae, and other strategies, such as phage therapy and vaccine strategies, are being developed to overcome these types of resistance.^96–98

Ceftazidime–avibactam (CAZ-AVI), ceftolozane–tazobactam (TOL-TAZ), meropenem–vaborbactam (MER-VAB) and imipenem/cilastatin–relebactam (IMI-REL) are recently reported to be active against Enterobacteriaceae, including ESBL-producing, AmpC-producing and carbapenemase producing isolates; and are also in ongoing trials for different populations and combinations with other antibacterial. Moreover, β-lactam–sulfone β-lactamase inhibitor combinations including cefepime–tazobactam and cefepime–enmetazobactam (AAI101), β-lactam–diazabicyclooctane β-lactamase inhibitor combinations including cefepime–zidebactam (WCK 5107), aztreonam–avibactam, sulbactam–durlobactam (ETX2514), meropenem–nacubactam (FPI-1465) and cefpodoxime proxetil-ETX0282; and β-lactam–boronate β-Lactamase inhibitor combinations such as cefepime–taniborbactam (VNRX-5133) and QPX7728 are in development processes and under clinical trials, which could be promising future treatment options against ESBL and carbapenemase-producing bacteria.⁹⁹

Possibly in the future many clinical trials and investigations have looked into the efficacy and resistance patterns of CAZ/AVI. Interestingly, the International Network for Optimal Resistance Monitoring (INFORM) studied more than 30,000 strains of Enterobacteriaceae obtained from patients with diverse bacterial illnesses and found that these microbes were more susceptible to the CAZ/AVI combination (99.5%).¹⁰⁰

Ceftazidime–avibactam is the primary treatment for CRE infections that produce OXA-48-like proteins. Ceftazidime–avibactam, meropenem–vaborbactam, and imipenem–cilastatin–relebactam have action against Enterobacteriaceae that produce KPC enzymes, which are the most frequent carbapenemase in the US.¹⁰¹

Conclusion and Recommendations

Finally, it is clear that carbapenem resistance in Enterobacteriaceae has developed substantially, posing a serious threat to global health. CRE have once again become a concern to civilization, as evidenced by a steady stream of publications describing resistant strains and sometimes novel resistance mechanisms. Dissemination and acquisition can go undetected, posing serious problems for infection control. Because the Enterobacteriaceae are a typical part of the gut microbiota, people might be colonized asymptomatically and unintentionally serve as a reservoir for spreading the bacteria to others; a subset of people will get illnesses as a result of these bacteria. Drug resistance mechanisms are varied and adaptable in these bacteria, making control and early identification of CRE infections difficult. As a result, a holistic approach must be adopted, which includes continued health-care professional education, infection control, interrupting the infection chain, antimicrobial stewardship in both humans and animals, and increased regional and international collaboration to slow the emergence of resistances. Existing antibiotics such as Fosfomycin, aminoglycosides, and colistin are currently used as therapeutic options for CRE infections, while Avibactam combined with carbapenem-containing regimens is a newly developed antibiotic. Plazomicin, eravacycline, cefiderocol, zidebactam, and nacubactam are among the novel agents in development as new agents for various Enterobacteriaceae.

References